Kiniksa Pharmaceuticals, Ltd. - (KNSA): Price and Financial Metrics
KNSA Price/Volume Stats
| Current price | $16.91 | 52-week high | $22.09 |
| Prev. close | $16.88 | 52-week low | $10.65 |
| Day low | $16.56 | Volume | 375,900 |
| Day high | $17.15 | Avg. volume | 400,533 |
| 50-day MA | $19.46 | Dividend yield | N/A |
| 200-day MA | $17.63 | Market Cap | 1.19B |
KNSA Stock Price Chart Interactive Chart >
Kiniksa Pharmaceuticals, Ltd. - (KNSA) Company Bio
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda
Latest KNSA News From Around the Web
Below are the latest news stories about KINIKSA PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate KNSA as an investment opportunity.
Chief Accounting Officer Michael Megna Sells 9,316 Shares of Kiniksa Pharmaceuticals Ltd (KNSA)Michael Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA), has sold 9,316 shares of the company on December 19, 2023, according to a recent SEC Filing. |
The 3 Most Undervalued Biotech Stocks to Buy in DecemberBiotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks. |
Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's HowKiniksa Pharmaceuticals (KNSA) enjoys a good run in the year on the back of solid revenue growth and pipeline updates. |
Wall Street Analysts See a 70.27% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High?The average of price targets set by Wall Street analysts indicates a potential upside of 70.3% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
7 Underappreciated Biotech Stocks to Pick Up on the CheapAmid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. |
KNSA Price Returns
| 1-mo | -14.60% |
| 3-mo | -10.43% |
| 6-mo | 10.89% |
| 1-year | 45.03% |
| 3-year | 2.42% |
| 5-year | 3.62% |
| YTD | -3.59% |
| 2023 | 17.09% |
| 2022 | 27.27% |
| 2021 | -33.39% |
| 2020 | 59.76% |
| 2019 | -60.63% |
Loading social stream, please wait...